Results 121 to 130 of about 6,306 (210)

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling. [PDF]

CPT Pharmacometrics Syst Pharmacol
Jonsson EN, Nyberg J, Mentré F.
europepmc   +1 more source

CPT: Pharmacometrics & Systems Pharmacology [PDF]

CPT: Pharmacometrics & Systems Pharmacology, 2013
openaire   +2 more sources

SCOUT: An Exploratory Approach to Scouting Dose-Relevant Covariates. [PDF]

CPT Pharmacometrics Syst Pharmacol
Ideno Y, Kasai H, Tanigawara Y.
europepmc   +1 more source

Correction to “Development of an Agent‐Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec”

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 8, August 2026.
wiley   +1 more source

Causal Directed Acyclic Graphs to Mitigate Confounding Bias in Exposure-Response Analyses. [PDF]

CPT Pharmacometrics Syst Pharmacol
Goulooze SC, Vong C, Hu C, Dumortier T, Mercier F.   +4 more
europepmc   +1 more source

Pharmacometrics in children

Proceedings for Annual Meeting of The Japanese Pharmacological Society, 2018
openaire   +2 more sources

Quantitative Systems Pharmacology Modeling Amid the Rise of Agentic AI. [PDF]

CPT Pharmacometrics Syst Pharmacol
Lu J, Desikan R.
europepmc   +1 more source

CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy

CPT: Pharmacometrics & Systems Pharmacology, 2017
MJ Garrido, P Berraondo, IF Trocóniz
openaire   +3 more sources

Development of an Agent-Based Model to Investigate Durability of Factor IX Activity in Hemophilia B Patients Treated With Etranacogene Dezaparvovec. [PDF]

CPT Pharmacometrics Syst Pharmacol
Li Y, Nandy P, Jordie E, Knab T, Peppel K, Kirouac DC, Wilkins AK, Nuthalapati S.   +7 more
europepmc   +1 more source

Optimizing Venous Thromboembolism Prophylaxis in Burn Patients Using Enoxaparin Through PBPK Modeling. [PDF]

CPT Pharmacometrics Syst Pharmacol
Mim SR, Yellepeddi VK, Azeredo FJ.
europepmc   +1 more source